Cell Therapy News

The uptake of chimeric antigen receptor T-cell therapy has been sluggish despite its tantalizing promise to provide a cure for a large proportion of patients with advanced large B-cell lymphoma.

American Society for Transplantation and Cellular Therapy will present three awards during this year’s TCT Meetings Digital Experience.

The FDA granted accelerated approval to lisocabtagene maraleucel for adults with relapsed or refractory large B-cell lymphoma who received at least two prior therapies.

Although colorectal cancer mortality has declined steadily since the 1940s, the long-term prognosis for patients with late-stage metastatic disease has remained relatively poor.

Challenges presented by the COVID-19 pandemic did not stop progress in research or clinical development of gene and cell therapies, according to a state-of-the-industry briefing by Alliance of Regenerative Medicine.

The FDA cleared an investigational new drug application for VX-880, a stem cell-derived therapy for patients with type 1 diabetes, according to the agent’s manufacturer.

The FDA lifted its clinical hold on a study evaluating BPX-601 and rimiducid for patients with previously treated metastatic pancreatic or prostate cancers, according to a press release from the agent’s manufacturer.

Little is known about the long-term issues facing cancer survivors who received chimeric antigen receptor T-cell therapy, primarily because the therapy is relatively new.

An allogeneic chimeric antigen T-cell therapy showed evidence of clinical activity among patients with metastatic colorectal cancer, according to results of a dose-escalation study presented at Gastrointestinal Cancers Symposium.

Jakub Svoboda, MD, of Penn Medicine, discussed data from the ZUMA-12 study presented at the ASH Annual Meeting and Exposition.